Drug makers fight to keep the name of their opiate-derived opiate from being banned

By TOM COLEMANAssociated PressMay 26, 2018 09:59:08Drug makers are trying to keep their name from being used as a marketing tool for the drug their opiates are designed to treat.

In a lawsuit filed in federal court in Atlanta, drug makers are fighting to stay the name. 

The names of several of the most commonly used prescription opiates in the United States, including oxycodone, hydrocodone and morphine, are being used to promote their products.

In a filing last week, the National Association of Manufacturers said the names are confusing because they are “not descriptive and do not describe the drugs pharmacologically.”

In the complaint, the drug companies also claim the names violate the law that requires drug companies to avoid misleading names or advertisements. 

Some companies have already moved to keep using the names of the drugs in their products, but others are waiting to see how that will play out. 

Drug companies are suing to stop the drug makers from using their brands in advertising.

For example, Pfizer Inc. and AstraZeneca AG sued to block the use of the drug Opana in the generic form that is now available for prescription, arguing the generic was too similar to its brand. 

In the case, the plaintiffs argue that the generic is too similar because it was made by Astra and Pfizer.

The complaint, filed on May 26, said the generic version of Opana sold for $70 a pill. 

Another company, Medtronic Inc., is suing to block use of Opaxan in the $50 generic version that was recently approved for sale.

The generic versions of the two drugs have not been approved for use as long as the drug names have been in use.

The generic version is currently available for $50 a pill from pharmacies and is also available over-the-counter.